Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V Motor Neurons in response to a...
Xinhua Silk Road: Inheriting traditions while promoting innovation, Chinese pharmaceutical company contributes to TCM globalization
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With continuous advancement of the Belt and Road Initiative, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. has been actively promoting the globalization of traditional Chinese medicine (TCM) through both inheriting traditional assets and engaging in modern innovations. The company, based in southeast China's Fujian Province, has been making continuing efforts in recent years...
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD’s The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by...
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to support the Company's strategy of HBV functional cure in broader patient populations...
SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN
BANGKOK, Nov. 19, 2024 /PRNewswire/ -- Siriraj Piyamaharajkarun Hospital (SiPH), operating under Faculty of Medicine Siriraj Hospital, today announced a successful transformation of its Pathology Information System (PIS) using advanced computational technologies and artificial intelligence. In collaboration with IBM (NYSE: IBM), the system now integrates laboratory workflows, image scanning systems, and centralized...
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a highly conserved serine/threonine protein kinase that plays a crucial role during cellular mitosis. It is overexpressed in various...
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted TAHO's proposal for a 505(b)(2) NDA submission, based on a single pivotal bioequivalence...
Beyond Living Unveils Malaysia’s First Non Wearable AI-Driven SOS Device
KUALA LUMPUR, Malaysia, Nov. 19, 2024 /PRNewswire/ -- Proudly Malaysian-born, Beyond Living introduces the AI SOS Device, Malaysia's first non-wearable, AI-powered life-saving solution. The device is tailored to meet the needs of active lifestyle athletes, elderly, adults living alone and individuals with heart concerns, filling a critical gap in the health tech market. Co-founders Justin and Victor have leveraged their...
GHIT Fund Awarded Open Philanthropy Grant to Expand Funding Sources for Global Health R&D
TOKYO, Nov. 19, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is pleased to announce that Open Philanthropy, a grantmaking organization based in San Francisco, California, has awarded funding for efforts to cultivate new partnerships and secure resources from the private sector and individual champions for global health R&D innovation, primarily in Japan, and will join GHIT as a new...
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments The two sides aim to submit an Investigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical...
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy...
